Want to see XTNT full AI Analyst Report?
Xtant Medical Holdings (XTNT) AI Stock Analysis
Xtant Medical Holdings
(NYSE MKT:XTNT)
XTNT’s score is primarily held back by unstable profitability and weak/volatile cash generation (including slightly negative TTM free cash flow). Technicals also remain a headwind with price below key moving averages and negative MACD. The latest earnings call adds risk due to reduced revenue guidance, margin pressure, and tighter liquidity, partially offset by credible commercial initiatives (Dilon/HEMOBLAST and salesforce expansion).
Xtant Medical Holdings (XTNT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $42.09M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.69M
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- 0.80
- Revenue Growth
- -14.27%
- EPS Growth
- -132.84%
- Country
- US
- Employees
- 151
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Xtant Medical Holdings Business Overview & Revenue Model
Company Description
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological sur...
How the Company Makes Money
Xtant Medical makes money primarily by selling medical devices and biologic products used in spine and orthopedic procedures. Its key revenue streams generally include: (1) Orthobiologics/biologics revenue from the sale of graft materials and related...
Xtant Medical Holdings Earnings Call Summary
The call presents meaningful strategic and commercial progress — notably the Dilon distribution agreement, integration of 17 new sales reps, product launches (Trivium Shaped) and expanded TAM — which position Xtant for future growth. However, the quarter showed significant near-term financial deterioration: sharp year-over-year revenue decline, gross margin compression, a swing to a net loss and negative adjusted EBITDA, reduced cash balances and a modestly reduced full-year revenue guide. Many negative results are tied to one-time transitions (asset sales, license cessation, Dilon integration) and strategic investments, but the immediate financial metrics are weak while visibility into near-term cash/earnings recovery remains uncertain.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Xtant modestly lowered full‑year 2026 revenue guidance to $99 million–$103 million (from $101 million–$105 million previously), citing lower‑than‑expected biologics revenue in Q2 and persistent headwinds in its amnio line through the back half of the year; Q2 revenue was $23.0 million (vs. $35.4M GAAP / $24.8M pro forma in Q2 2025), gross margin was 57.9% (vs. 68.6% LY) and adjusted EBITDA was a loss of $2.7 million (vs. +$6.9M LY). Management stressed it still expects accelerating sequential biologics growth in H2 as the newly integrated Dilon team (17 reps + 2 regional managers) and an expanded field organization (now >25 reps and multiple national accounts) are fully deployed; HEMOBLAST contributed ~$1.5 million in Q2 (primarily recognized net—approximately $600k–$700k of additional revenue would have been recognized if shipped under Xtant POs), and the company continues to model HEMOBLAST transactional volume at over $1 million per month on a gross basis once transitions complete.
Xtant Medical Holdings Financial Statement Overview
Summary
Fundamentals are mixed with elevated volatility. Gross margins remain fairly solid, and leverage has improved versus prior periods, but TTM profitability deteriorated back to operating and net losses after a profitable 2025. Cash generation is the main weakness: TTM operating cash flow is modest and free cash flow turned slightly negative, limiting flexibility.
Income Statement
48NeutralBalance Sheet
63PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 109.53M | 133.93M | 117.27M | 91.30M | 57.97M | 55.26M |
| Gross Profit | 65.05M | 84.27M | 68.22M | 55.47M | 32.14M | 32.49M |
| EBITDA | -2.45M | 15.89M | -7.88M | 5.08M | -5.43M | -2.52M |
| Net Income | -11.14M | 4.97M | -16.45M | 660.00K | -8.48M | -4.85M |
Balance Sheet | ||||||
| Total Assets | 79.67M | 94.14M | 93.84M | 92.61M | 60.23M | 54.69M |
| Cash, Cash Equivalents and Short-Term Investments | 9.87M | 17.05M | 6.20M | 5.71M | 20.30M | 18.24M |
| Total Debt | 26.01M | 28.72M | 35.14M | 23.56M | 17.07M | 16.84M |
| Total Liabilities | 39.65M | 43.19M | 50.87M | 41.26M | 26.06M | 23.81M |
| Stockholders Equity | 40.02M | 50.95M | 42.96M | 51.35M | 34.17M | 30.88M |
Cash Flow | ||||||
| Free Cash Flow | -696.00K | 10.16M | -16.01M | -10.97M | -7.11M | -1.68M |
| Operating Cash Flow | 570.00K | 12.55M | -11.90M | -9.52M | -5.34M | 439.00K |
| Investing Cash Flow | 14.39M | 7.90M | -3.73M | -24.78M | -1.56M | -1.89M |
| Financing Cash Flow | -12.03M | -9.57M | 16.07M | 19.69M | 9.02M | 17.50M |
Xtant Medical Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTNT, the sentiment is Positive. The current price of 0.30 is above the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.33, and below the 200-day MA of 0.45, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.87 is Neutral, neither overbought nor oversold. The STOCH value of 36.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XTNT.
Xtant Medical Holdings Risk Analysis
Xtant Medical Holdings disclosed 55 risk factors in its most recent earnings report. Xtant Medical Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskXtant Medical Holdings Peers Comparison
Overall Rating
SYK75Outperform
ZBH69Neutral
BVS66Neutral
OFIX50Neutral
IART47Neutral- XTNT44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SYK | 75Outperform | $129.30B | 35.46 | 15.61% | 1.05% | 7.87% | 22.82% |
| ZBH | 69Neutral | $21.01B | 26.91 | 6.05% | 0.90% | 6.98% | -2.22% |
| BVS | 66Neutral | $962.26M | 12.62 | 27.23% | ― | 3.87% | 623.68% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| OFIX | 50Neutral | $395.92M | -5.81 | -14.05% | ― | 2.99% | 51.77% |
| IART | 47Neutral | $1.15B | 84.15 | 1.24% | ― | 0.84% | ― |
| XTNT | 44Neutral | $41.53M | -3.65 | -23.45% | ― | -14.27% | -132.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XTNT | Xtant Medical Holdings Inc | 0.30 | -0.45 | -60.11% | |
| IART | Integra Lifesciences | 14.12 | 2.08 | 17.28% | |
| OFIX | Orthofix Medical Inc. | 8.92 | -6.04 | -40.37% | |
| SYK | Stryker Corp | 335.08 | -17.05 | -4.84% | |
| ZBH | Zimmer Biomet Holdings | 106.85 | 19.29 | 22.03% | |
| BVS | Bioventus, Inc. | 10.68 | 3.23 | 43.36% |
Xtant Medical Holdings Corporate Events
Xtant Medical Stockholders Approve Governance and Leadership Items
PositiveOn August 7, 2026, Xtant Medical Holdings, Inc. held its Annual Meeting of Stockholders, with a quorum of 74.47% of outstanding common shares present or represented by proxy. Six board nominees were elected to serve until the next annual meeting, wit...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026